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Under drugs and the cardiovascular system, six topics are to be considered.  In this chapter 
drugs for hypertension, drugs for angina, and drugs for heart failure are considered, and in the 
next chapter, drugs for cardiac arrhythmias, anti-thrombotic drugs, and lipid modulating 
drugs.  
 
 
12.1 Drugs for hypertension 
 12.1.1 Epidemiology and pathophysiology 
Hypertension is high blood pressure, and is defined as anything  140 systolic/90 diastolic 
mm Hg.  It is very common disorder; 3.7 million Australians have hypertension or are being 
treated for hypertension, which about one-third of the population.  Indeed hypertension is the 
most common cardiovascular disease.  The incidence increases with age, such that at birth 
and in the young, there is a low incidence of hypertension.  During middle age, there is an 
increasing incidence of hypertension, and by old age, there is a very high incidence.  
Hypertension is considered to be “the silent killer” as, unless the blood pressure is extremely 
high, there are no symptoms.  Nevertheless the hypertension is doing harm.  Hypertension is 
the leading risk factor for mortality (death). High blood pressure alone does not kill you, it 
is the things it does that hurt or kill you.  Hypertension is the principle cause of stroke.  
Hypertension leads to coronary artery disease with myocardial infarction and sudden cardiac 
death.  Hypertension is the major contributor to retinal haemorrhage (bleeding in eye), heart 
failure, renal insufficiency, and dissecting aneurysm of aorta (splitting of aorta). 
 
The majority of people with hypertension have essential hypertension.  In essential 
hypertension, the cardiac output is normal, but the total peripheral resistance is increased.  
The exact cause of essential hypertension is unknown.  It is the combination of genetic 
disease with many loci involved, and environmental factors.  The environmental factors 
include several aspects of a Western lifestyle; stress, smoking, salt, and obesity. 
 
Essential hypertension is associated with pathological changes in heart and blood vessels.  
These pathological changes are compensatory changes to maintain cardiac output in the face 
of increasing total peripheral resistance. The heart has a thickening of the left ventricular 
wall, and this is known as hypertrophy (cardiac hypertrophy).  The arteries also have 
hypertrophy of the smooth muscle, and injury to the endothelial cells lining the blood vessels. 
 
The non-pharmacological treatments of hypertension that are effective an decreasing blood 
pressure include a body weight reduction, restricting the amount of Na
+
 in the diet, and 
initiating or increasing exercise.  Blood pressure is also lowered when people avoid excessive 
alcohol or manage to decrease the stress in their lives. 
 
In essential hypertension, the underlying cause is not singular, and this means we do not have 
a single target for a drug to attack.  The treatment of essential hypertension is to lower blood 
pressure by any mechanism, preferable with as few side effects as possible.  As subjects with 
hypertension lack symptoms, they are intolerant of adverse effect with drugs for 
hypertension.  Other the years, drugs for hypertension have been developed that have few 
side effects, and subjects are often prepared to take these on a regular basis.  Often diuretics, 
drugs that increase water loss from the body, are the initial drugs used to treat essential 
hypertension. 
  
 12.1.2 Diuretics for hypertension 
Diuretics are drugs that increase the loss of water from the body.  In hypertension, a common 
diuretic treatment is the combination of a thiazide diuretic and a K
+
-sparing diuretic 
(amiloride).  The diuretics act at different parts of the kidney tubule.  The thiazide diuretics 
act on the distal convoluted tubule, and the K
+
-sparing diuretics act on the collecting duct.  
Another class of diuretics, the loop diuretics (which are used mainly in the treatment of heart 
failure) act on the loop of Henle. 
 
In the distal tubule (just before the collecting duct) of the kidney, thiazide diuretics inhibit 
the Na
+
Cl
-
 co-transporter (Figure 12.1.1), which inhibits Na
+
 reabsorption to increase the 
levels of Na
+
 and Cl
-
 in urine.   
 
Figure 12.1.1 Mechanism of action of thiazide diuretics (Copyright QUT, Sheila Doggrell) 
 
As water reabsorption passively follows electrolyte reabsorption along the kidney tubule, 
when the levels of Na
+
 and Cl
-
 in urine are increased, so are the levels of water in the urine.  
This decreased water reabsorption leads to increased water loss from the body, which in turn 
leads to decreased blood volume, decreased venous return and decreased blood pressure. 
 
The thiazide diuretics are active after oral administration, which makes them easy to use.  
They are secreted into the proximal tubule of the kidney, and pass along the kidney tubule to 
the distal tubule, where they inhibit the Na
+
Cl
-
 cotransporter in the distal tubule.  With most 
thiazide diuretics, there is a diuretic effect within an hour, and a modest maximal effect is 
observed i.e. increase in water loss is modest.  The main difference between the thiazide 
diuretics is there duration of action with hydrochlorothiazide, a commonly used thiazide 
diuretic, having a duration of action of ten hours, which allows it to be used once or twice 
daily.  After having their effect, the thiazide diuretics are excreted in urine.  They are a 
common initial treatment for hypertension, often in combination with a K
+
-sparing diuretic, 
an ACE inhibitor or an AT1-receptor antagonist.  
 
The thiazide diuretics are well tolerated, and have only a few adverse effects.  They can cause 
hypokalemia (low levels of potassium), as increasing the amount of water/Na
+
 delivered to 
the collecting duct increases K
+
 loss.  This problem with the thiazide diuretics can be 
overcome by using them with a K
+
 sparing diuretic (e.g. amiloride).  The second adverse 
effect observed with the thiazide diuretics is hyperuricemia, due to increased uric acid 
reabsorption.  Thus, thiazides should not be given to subjects prone to gout, which is due to 
the accumulation of uric acid in joints. 
 
To prevent excess K
+
 loss, thiazide diuretics are often administered with a K
+
-sparing 
diuretic.  Amiloride is a K
+ 
sparing diuretic.   Amiloride inhibits a sodium channel in the late 
distal tubule/collecting duct (Figure 12.1.2), and this decreases Na
+
/K
+ 
pumping, and the 
amount of K
+
 available for loss/secretion through the K
+ 
channel.   Overall, there is an 
inhibition of the exchange of sodium for potassium in the late distal tubule/collecting by 
amiloride.   
 
Figure 12.1.2 Mechanism of action of amiloride (Copyright QUT, Sheila Doggrell) 
 
Thus, amiloride indirectly inhibits K
+
 secretion (loss) into the kidney.  Although, it is called a 
diuretic, amiloride only has a small diuretic effect, with its main use being to prevent the 
excess K
+
 loss with the thiazide diuretics.  Amiloride is used in combination with a thiazide, 
often as a single tablet (e.g. amiloride/hydrochlorothiazide), to prevent K
+ 
loss.  The most 
common adverse effect with amiloride is hyperkalemia (high levels of potassium), which is 
an obvious result from preventing K
+
 loss. 
 
Thiazide diuretics only have a modest effect on blood pressure, typically lowering it by < 10 
mm Hg. Thus, when blood pressure remains high or, as the hypertension progresses, becomes 
high, other anti-hypertensive drugs are added to the diuretics, and these include vasodilators 
and β-adrenoceptor antagonists.   
 
 12.1.3 Vasodilators for hypertension 
Some drugs cause vasodilation, and some drugs reverse vasoconstriction to effectively cause 
vasodilation, and I refer to both of these mechanisms as vasodilation. 
 
Three groups of vasodilators are used in the treatment of hypertension, inhibitors of the renin-
angiotensin system (angiotensin converting enzyme inhibitors and AT1 receptor antagonists), 
Ca
2+
 channel blockers, and α1-adrenoceptor antagonists. 
 
Angiotensin II is a potent vasoconstrictor, stimulates hypertrophy, and stimulates aldosterone 
secretion.  Aldosterone causes salt and water retention, and fibrosis (the laying down of 
collagen in the heart), which all worsens the hypertension.  Angiotensin converting enzyme 
has a key role in the renin-angiotensin-aldosterone system. It is involved in the conversion of 
angiotensin I, which is an inactive decapeptide to angiotensin II, the active octapeptide.  
Angiotensin converting enzyme is also involved in the breakdown of bradykinin.  
Bradykinin is a potent vasodilator, which is broken down in the presence of angiotensin 
converting enzymes to inactive fragments.  
 
When angiotensin converting enzyme is inhibited with an angiotensin converting enzyme 
(ACE) inhibitor, there are decreased levels of angiotensin II, and aldosterone (Figure 
12.1.3). 
 
Figure 12.1.3 ACE inhibition (Copyright QUT, Sheila Doggrell). 
 
As angiotensin II and aldosterone both increase blood pressure, lowering their levels, will 
decrease blood pressure.  ACE inhibitors will also decrease the breakdown of bradykinin 
increasing the levels of this vasodilator, which will also contribute to the decrease in blood 
pressure observed with ACE inhibitors. 
 
The ACE inhibitors all have names that end in PRIL, such as enalapril.  The prils are used as 
vasodilators in the treatment of hypertension.   Enalapril is available alone in a tablet or in 
combination with hydrochlorothiazide.  Enalapril is metabolised in the gut to the ACE 
inhibitor enalaprilat, which has a 60% bioavailability after oral administration.  Enalaprilat 
will decrease the levels of angiotensin II (vasoconstrictor), decrease levels of aldosterone 
(Na
+
 and water retention) and increase the levels of the vasodilator bradykinin.  All of these 
effects contribute to the ability of enalapril to decrease blood pressure. 
 
Enalaprilat is predominantly eliminated by kidneys, which means the dose needs to be 
reduced in renal impairment to avoid increased levels and excessive vasodilation.  The prils 
can adversely cause a dry cough, which is quite common, and angiodema (rare).  Both of 
these conditions are probably due to the accumulation of bradykinin that has many effects 
other than vasodilation.  These adverse effects do not occur with the angiotensin II receptor 
antagonists, as these have no effect on bradykinin levels.  People who cannot tolerate ACE 
inhibitors are often transferred to AT1 receptor antagonists, which do not alter the levels of 
bradykinin. 
 
The majority of the cardiovascular effects of angiotensin II are mediated by AT1-receptors.  
AT1-receptor antagonists have names ending in sartan.  The sartans, such as candesartan, 
inhibit effects mediated by AT1 receptors to decrease vasoconstriction (effectively 
vasodilation) decrease hypertrophy, and decrease aldosterone secretion and the effects of 
aldosterone (Figure 12.1.4). 
 
Figure 12.1.4 AT1-receptor antagonism (Copyright QUT, Sheila Doggrell) 
 
Candesartan is available alone or in combination with hydrochlorothiazide (thiazide 
diuretic).  The adverse effects with ACE inhibitors of dry cough and angiodema (rare) do not 
occur with AT-1 antagonists.  
 
By reducing blood volume, diuretics stimulate the renin-angiotensin system.  This sensitizes 
(makes the effects bigger) the patients to ACE inhibitors and AT-1 antagonists, making the 
combination of a diuretic and an ACE inhibitor or AT-1 antagonist more effective at reducing 
blood pressure than either a diuretic alone, or an angiotensin II inhibitor alone. 
 
The ACE inhibitors and the AT-1 receptor antagonist (Angiotensin Receptor Antagonist, 
ARBs) are contraindicated in pregnancy.  Hypertension is quite common in pregnancy, and 
the ACE inhibitors and ARBS must not be used to treat any hypertension associated with 
pregnancy.  If they are used in first semester, the ACE inhibitors and ARBs cause major 
congenital malformations, which are defects/damage to developing fetus.  This is probably 
because angiotensin II has a major role in fetal development.  If the ACE inhibitors or ARBs 
are uses in second and third semester, they cause fetal renal dysfunction and oligohydramnios 
(deficiency in amniotic fluid), and can lead to fetal death.  
 
The second group of vasodilators used in the treatment of hypertension are the Ca
2+
 entry 
blockers.  Ca
2+
 entry blockers are also known as Ca
2+
channel blockers, and Ca
2+
 antagonists.  
Regardless of what is contracting the blood vessel, whether it is depolarization or 
noradrenaline acting at α-adrenoceptors or 5-HT acting at 5-HT2-receptors, contraction of 
vascular smooth muscle requires Ca
2+
 entry into cells through Ca
2+
 channels (Figure 12.1.5).  
This makes Ca
2+
 channel blockers are effective against all vasoconstrictors. 
 
Figure 12.1.5 Ca
2+
 channels and vasoconstriction (Copyright QUT, Sheila Doggrell) 
 
An example of a calcium channels blocker is amlodopine.  Amlodopine has a greater effect 
on the blood vessels than the heart, and thus causes vasodilation with little effect on the heart.  
Amlodopine is available as a once a day preparation.  Amlodopine is used in the treatment of 
essential hypertension.  With calcium channel blockers, the most common side effects are 
related are extensions of the therapeutic effect to excessive vasodilation causing headache, 
flushing, and dizziness. 
 
The third class of vasodilator used in the treatment of hypertension are the α1-adrenoceptor 
antagonists, such as prazosin.  On activation of the sympathetic nervous system, 
noradrenaline is released and stimulates α1-adrenoceptors on blood vessels to cause 
vasoconstriction.  Prazosin will bind to the α1-adrenoceptor to reduce the binding of 
noradrenaline, and the resulting vasoconstriction, effectively causing vasodilation and 
reducing blood pressure.  α1-Adrenoceptor antagonists can only be used to cause small 
decreases in blood pressure, as excessive vasodilation leads to adverse effects.  Presently, 
prazosin is occasionally used in combination with other anti-hypertensive drugs.  For 
instance, if the combination of a diuretic and a β-blocker fails to control blood pressure, an 
α1-adrenoceptor antagonist may be added. 
 
 12.1.4 β-Adrenoceptor blockers for hypertension 
The third group of drugs commonly used in the treatment of hypertension are the β-
adrenoceptor antagonists (β-blockers).  On the heart, noradrenaline stimulates β1-
adrenoceptors to increase heart rate and heart force, and on the kidney, noradrenaline 
stimulates β1-adrenoceptors to increase renin production, and hence angiotensin II and 
aldosterone production.  Angiotensin II causes vasoconstriction and aldosterone causes salt 
and water retention, and both of these effects increase blood pressure.  Thus, a β1-
adrenoceptor antagonist e.g. atenolol will effectively decrease these effects to cause a 
decrease in heart rate and force, and a decrease in vasoconstriction and salt and water 
retention.   The β1-adrenoceptor antagonist atenolol is commonly used in the treatment of 
essential hypertension.  Atenolol is active after oral administration.  Atenolol is hydrophilic, 
which means there is little penetration of central nervous system and no centrally mediated 
adverse effects, such as nightmares.  Atenolol has an elimination t1/2 of 5-8 h, which allows 
once-a-day administration.  Atenolol is excreted, largely unchanged, in urine, which means 
that a downward dosage adjustment may be needed in renal failure to prevent adverse effects. 
 
The β-adrenoceptor blockers are contraindicated in subjects with asthma.  These, and other 
details relating to β-adrenoceptor blockers, were discussed in detail in Chapter 7.  
 
12.2 Drugs for angina 
 
 12.2.1 Typical angina 
Angina pectoris means “choked chest”, which is a description of the symptoms in angina 
pectoris.  Angina pectoris is a heavy, pressing, substernal discomfort with pain that often 
radiates to the left shoulder. Subjects with angina pectoris describe a feeling of suffocation 
and impending death.  Angina pectoris is due to an imbalance between oxygen supply and 
oxygen demand due to coronary artery disease.  Thus, the diseased coronary arteries are 
unable to supply enough oxygen to meet the demands of the heart.  The coronary artery 
disease limits the blood supply. In coronary artery disease lipids including cholesterol 
contribute to the thickening of the artery walls, and with platelets and other blood 
components form plaques (Figure 12.2.1).  The reduced lumen of the blood vessel reduces 
blood flow. 
 
Figure 12.2.1 Coronary artery disease (Copyright QUT, Sheila Doggrell) 
 
Angina pectoris is a progressive disease.  In the initial stable phase, attacks of angina do no 
occur at rest, but occur with exercise and stress.  Stable angina is associated with thickening, 
but not usually with plaque in the coronary arteries.   
 
The mechanism underlying the attack of typical angina is that during stress or exercise, there 
is activation of the sympathetic nervous system with increased release of noradrenaline and 
increase stimulation of cardiac β1-adrenoceptors.  This stimulation leads to an increased heart 
rate, heart force, and, consequently, of the work done by the heart.  To support this work, the 
heart has an increased demand for oxygen and nutrients, which are supplied by the coronary 
circulation.  In stress or during exercise, the reduced blood flow in diseased coronary is 
inadequate to meet the oxygen and nutrient demand, and this gives an attack of angina. 
 
Unstable typical angina is worsening of stable angina, so that angina attacks occur when the 
subject is at rest.  Unstable angina is associated with thickening of the blood vessels and 
plaque formation in the coronary arteries.  This is a very precarious position to be in, as 
plaque rupture with the subsequent blockade of smaller vessels leads to myocardial 
infarction (heart attack). 
 
The drugs used to treat typical angina are divided into those used during an attack and those 
to prevent an attack of angina. 
 
 12.2.2 Drugs to treat an attack of typical angina 
The group of drugs used to treat an attack of angina are the nitrovasodilators (nitroglycerin 
and isosorbide dinitrate), which are used sublingually to get a quick effect (relief of attack). 
The nitrovasodilators mimic the effect of endogenous nitric oxide (NO).  Nitric oxide 
stimulates guanylate cyclase, leading to increased intracellular cGMP, which promotes the 
relaxation of smooth muscle including vascular smooth muscle (Figure 12.2.2).  The 
nitrovasodilators release nitric oxide, which has the same effect as the endogenous NO. 
 
Figure 12.2.2 Nitrovasodilators (Copyright QUT, Sheila Doggrell) 
 
Normal coronary arteries are dilated by nitrovasodilators.  Diseased coronary arteries have 
lost their elasticity, and are difficult to dilate.  Thus, nitrovasodilators only cause a small 
dilation of diseased coronary arteries, and this alone does not explain the benefit of 
nitrovasodilators in typical angina.  Nitrovasodilators end an angina attack by causing 
venodilation (dilation of veins).  Venodilation leads to pooling of the blood in the veins, 
which reduces venous return, which (in turn) reduced the work done by the heart, and reduces 
the oxygen demand.  This does not improve the function of the coronary arteries, but rather 
reduces the oxygen demand of the heart to level that can be met by the diseased coronary 
arteries. 
 
Nitroglycerin has extensive first pass liver metabolism, which means it is not active after 
oral administration.  Nitroglycerin is used as a sublingual tablet or spray to avoid first pass 
liver metabolism.  The other advantage of sublingual over oral is that it is a faster way to 
provide the nitroglycerin to the circulation in an attack of typical angina.  With 
sublingual/spray of nitroglycerin, the onset of action is within a minute, and the half-life (t1/2) 
is about 3 minutes, and this is ideal for the treatment of typical angina.  Nitroglycerin can also 
be used in the prevention of an attack of angina, where patches or ointment are used for the 
prevention of angina attacks. 
 
Isosorbide mononitrate is a nitrate that is resistant to first pass liver metabolism.  This 
means that it active after oral administration and has a longer half-life (3-6 hours) than 
nitroglycerin.  Thus, after nitroglycerin has ended the attack of angina, isosorbide 
mononitrate can be used to prevent a further attack of angina. 
 
 12.2.3 Drugs to prevent an attack of typical angina 
Three groups of drugs are used to prevent attacks of typical angina; the nitrovasodilators, the 
β-adrenoceptor blockers (such as metoprolol and atenolol) and Ca2+ channel blockers.  
Verapamil is the Ca
2+
 channel blocker used in an attack of angina, as it has a more 
pronounced effect on the heart than on the blood vessels.  Like nitrovasodilators, -
adrenoceptor blockers and Ca
2+
 -channel blocker decrease the work done by the heart/O2 
demand to levels that can be met by the diseased coronaries. 
 
The nitrovasodilators used to prevent attacks of typical angina are nitroglycerin patches, 
which are applied topically to provide slow release of the nitrovasodilators.  As isosorbide 
mononitrate has no significant first pass liver metabolism, it can be used orally to prevent 
angina attacks.  
 
Long term treatment with nitrates is associated with tolerance (reduced effect) to nitrates for 
which the mechanism is unknown.  To prevent this reduced effect, drug holidays are used to 
prevent tolerance from developing.  This can be achieved by not applying the patch or 
ointment overnight. 
 
Both β-adrenoceptor antagonists and the Ca2+-channel antagonist verapamil interrupt the 
process in an attack of typical angina.  In the stable form of typical angina, exercise or stress 
provoke an attack by increasing the activity of the sympathetic nervous system and hence the 
release of noradrenaline, which acts at the cardiac β1-adrenoceptors to increase the heart rate 
and force, and the work done by the heart, which increases the oxygen demand to above that 
supplied in the diseased coronary arteries (Table 12.2.1).   β-adrenoceptor antagonists inhibit 
the binding of the noradrenaline to the cardiac β1-adrenoceptors to decrease the heart rate and 
force, and the work done by the heart, which decreases the oxygen demand to that supplied in 
the diseased coronary arteries to end the attack of angina (Table 12.2.1). 
 
Table 12.2.1 Preventing an attack of typical angina (Copyright QUT, Sheila Doggrell) 
 
The Ca
2+
-channel blocker verapamil inhibits at one stage later in the process of typical angina 
than the β-adrenoceptor antagonists.  Verapamil inhibits the influx of Ca2+, and this leads to a 
decreased heart rate and force, and thus work done by the heart and oxygen demand.  The 
goal is to decrease the oxygen and nutrient demand to the level that can be met by the 
diseased coronary arteries. 
  
12.2.4 Atypical angina 
Atypical angina is due to coronary artery spasm.  The spasm closes the blood vessel, and 
gives the same symptoms as typical angina.  As contraction of vascular smooth muscle 
requires Ca
2 +
 entry into cells through Ca
2+
 channels, Ca
2+
 channel blockers, which act 
predominantly on the blood vessels (e.g. amlodopine) are effective in atypical angina.  
 
12.3 Drugs for heart failure 
 
Heart failure is anything that leads to a reduced cardiac output.  Chronic heart failure is when 
the heart failure is ongoing, and drugs for chronic heart failure are the topic of this chapter. 
 
 12.3.1 The heart failure epidemic 
Heart failure is one of the most common causes of death and disability.  Congestive Heart 
Failure (CHF) is when heart failure is accompanied by congestion in the lungs.  The 
prevalence of Congestive Heart Failure in Australia, as elsewhere increases with age.  In 
Australia, at 50-59 years of age, 1% of subjects have CHF, after 60 years of age, 13% have 
CHF, and over 85 years of age, 50% have heart failure.  CHF is deadly, with a mortality rate 
of 50% at 5 years.  At present, 300,000 Australians have CHF with 30,000 new cases 
annually.  CHF is also an expensive disease with one-third of hospitalisation in the over 70 
years being due to CHF. 
 
Until fairly recently, hypertension and angina led to premature deaths due to heart attacks. 
However, good pharmacotherapy for hypertension, angina and heart attacks has reduced the 
deaths from heart attack, and subjects live on to get heart failure.  There is also a general 
ageing of the population with life expectancy continually increasing in most Westernised 
countries.  Thus, there is an increased incidence of old people with CHF. 
 
With the reduced cardiac output that is heart failure, there is poor delivery of oxygen and 
nutrients to the tissues of the body.  In heart failure, there is also reduced removal of carbon 
dioxide and waste materials from the tissues. 
 
 12.3.2 Compensatory changes in heart failure 
There are some compensatory changes associated with heart failure that are aimed at 
increasing cardiac output, but lead to the symptoms of heart failure.  When cardiac output is 
reduced, there is activation of the sympathetic nervous system to increase heart force and 
of the renin-angiotensin-aldosterone system. Both of these systems have a role in 
increasing blood pressure, which will initially help oxygen delivery and removal of waste 
from tissues.  However, with increased blood pressure, there is increased loss of fluid from 
blood vessels, and the fluid has to go somewhere, so there is increased fluid accumulation in 
legs, which is known as peripheral oedema.  Peripheral oedema leads to the swelling of the 
legs, which is a common symptom of heart failure. 
 
The increased peripheral arteriolar resistance (blood pressure) also leads to decreased renal 
blood flow, and a decreased glomerular filtration.  With a decreased glomerular filtration, the 
kidney cannot function properly, and there is an increased retention of water and electrolytes.  
Again this fluid has to go somewhere and it often goes to the lungs to cause pulmonary 
oedema, which underlies the difficulty in breathing, which is a common symptom of heart 
failure.  Poor kidney function will also contribute to peripheral oedema.  
 
 12.3.3 Diuretics for heart failure 
In hypertension, there is no accumulation of excessive fluid, but diuretics reduce blood 
pressure.  In heart failure, there is an accumulation of excessive fluid, so that it is much more 
logical to use diuretics in heart failure to remove excessive fluid.  By increase water loss from 
the body, diuretics decrease the oedema (Figure 12.3.1).   
 
Figure 12.3.1 Diuretics and heart failure (Copyright QUT, Sheila Doggrell) 
 
Diuretics decrease the oedema in the peripheral tissues, which leads to a reduced swelling of 
the legs.  Diuretics also decrease the pulmonary oedema, which has two effects.  Firstly, there 
is improved breathing, and secondly there is a decreased pulmonary resistance, which allows 
an increased cardiac output (Figure 12.3.1). 
 
The diuretic combination most commonly used in heart failure is a Loop/High Ceiling 
Diuretic (usually furosemide), often in combination with a K
+
-sparing diuretic (e.g. 
amiloride).  Amiloride has already been discussed.  The thiazide diuretics, which are used in 
the treatment of hypertension, are often not potent enough to give a good clearance of fluids, 
and the more potent furosemide is used.  Furosemide inhibits the Na
+
K
+
2Cl
-
 cotransporter in 
the thick ascending limb of Henle (Figure 12.3.2). 
 
Figure 12.3.2 Mechanism of action of furosemide (Copyright QUT, Sheila Doggrell) 
 
Furosemide (which is also known as frusemide) is active after oral or intravenous 
administration.  After oral administration, frusemide is readily absorbed from the 
gastrointestinal tract to give a diuretic effect within 30 minutes.  In an emergency, 
intravenous furosemide can be used to have an effect within 2 to 10 minutes.  Frusemide is 
actively secreted into the proximal tubule of the kidney, and passes along the kidney tubule to 
the thick ascending limb of Henle, where it inhibits the Na
+
K
+
2Cl
-
 cotransporter (Na
+
 
reabsorption).   As water reabsorption follows ion reabsorption, inhibition of the Na
+
K
+
2Cl
-
 
cotransporter leads to retention of ions and water, to increase the amount of water loss from 
the kidney.   Frusemide has a greater maximum diuretic effect than thiazide diuretics, and this 
is commonly needed in congestive heart failure.  Frusemide has a duration of action of 4 to 8 
hours, and is excreted in urine. 
 Unfortunately, the increase diuretic potency with frusemide comes with increased adverse 
effects.  An extension of the beneficial effects of frusemide leads to too much sodium being 
lost from the body producing hyponatremia (low levels of sodium in the body) and too 
much loss of fluid leading to hypotension.   
 
Frusemide can cause excessive K
+
 loss from the kidney, as increasing the volume of luminal 
fluid/Na
+
 in distal tubule promotes secretion of K
+
 into the kidney tubule, and K
+
 loss. This 
hypokalaemic (low levels of potassium) can promote cardiac arrhythmias.  Thus, when 
frusemide is being used on an ongoing basis, it may be necessary to determine plasma K
+
 
levels.  If excessive K
+
 is being lost from the body, frusemide can be given with potassium 
supplements or in combination with the K
+
 sparing diuretic amiloride.   
 
Frusemide can cause hyperuricemia (high levels of uric acid).  This is due to furosemide and 
uric acid being secreted into the proximal tubule by the same mechanism, and consequently 
furosemide can inhibit uric acid secretion and excretion.  When uric acid excretion is 
inhibited, the levels rise, and this precipitates attacks of gout, especially in people with a 
previous history of gout.  Thus, frusemide use should be avoided in this group, if possible.  
Frusemide can cause ototoxicity (hearing loss) by an unknown mechanism.  Fortunately, 
hearing loss with frusemide is reversible.  Finally, frusemide can increase the loss of 
magnesium from the body, and the resulting hypomagnesemia can promote cardiac 
arrhythmias. There hypomagnesemia-induced arrhythymias can be prevented with oral 
magnesium supplements. 
 
 12.3.4 ACE inhibitors, AT1-receptor antagonists, and aldosterone receptor 
antagonists 
The second group of drugs commonly in heart failure are the inhibitors of the renin-
angiotensin-aldosterone system, the angiotensin converting enzyme (ACE) inhibitors, AT1-
receptor antagonists, and aldosterone receptor antagonists.  Enalapril is an ACE inhibitor, 
and losartan is an AT-1 receptor antagonist used in heart failure.  These drugs have benefits 
due to venodilation and arteriolar dilation.   
 
In heart failure, drugs that cause venodilation, such as enalapril and losartan, lead to a 
pooling to the blood in veins.  With pooling of blood in the veins, less fluid needs to be 
dumped in the lungs, and the decreased fluid in the lungs makes breathing easier.  Also, 
decreasing the accumulation of fluid in the lung (caused by the compensatory changes in 
heart failure), leads to reduced pulmonary resistance making it easier for the heart to pump, 
and an improved myocardial performance is observed. 
 
Arteriolar dilation with enalapril and losartan also has beneficial effects in heart failure, and 
these effects are not observed in the normal heart.  In the normal heart, cardiac output is 
independent of peripheral arteriolar resistance.  Thus, graphically plotting cardiac output 
against arterial resistance in the normal heart there is no connection.  Regardless of arteriolar 
resistance, cardiac output is constant (Figure 12.3.3).  This is because, in the normal heart, as 
resistance is increased, so is heart rate, and cardiac output remains unchanged. 
 
Figure 12.3.3 Arteriolar resistance and cardiac out (Copyright QUT, Sheila Doggrell) 
 
However, the situation is very different in the failing heart, as the mechanisms to maintain 
cardiac output are already turned on, and in the failing heart, heart rate is at a maximum and 
cannot be increased.  Thus, as resistance is increased cardiac output is decreased (Figure 
12.3.3).  When arteriolar dilators, such as enalapril and losartan are used in heart failure, there 
is a decrease in arteriolar resistance, and an increase in cardiac output (Figure 21.3), but this 
only applies in the failing heart not the normal heart. 
 
The heart failure, there is excessive accumulation of sodium and water.  Aldosterone is the 
salt and water retention hormone.  The levels of aldosterone are elevated in subjects with 
heart failure.  Consequently, antagonists of aldosterone receptors are used in the treatment of 
heart failure.  Spironolactone is an antagonist at aldosterone receptors.  In the presence of 
aldosterone, spironolactone promotes the loss of sodium and water.  In a large clinical trial, 
spironolactone has been shown to decrease the mortality (deaths) and hospitalization of 
people with heart failure.  In the low doses used in the treatment of heart failure, the most 
common adverse effects of spironolactone are extensions of its beneficial effects.  Thus, 
spironolactone can cause hyperkalemia (retention of too much potassium leading to high 
potassium levels), and hyponatremia (loss of too much sodium leading to low levels of 
sodium in the body). 
  
 12.3.5 β-adrenoceptor antagonists 
For many years, it was considered that β-adrenoceptor antagonists would be detrimental in 
heart failure. Thus, 1-adrenoceptor antagonists were used in the treatment of hypertension 
and angina, but contraindicated in the treatment of heart failure.  Recently, 1-adrenoceptor 
antagonists have been shown to be beneficial in heart failure. On the normal heart, 1-
adrenoceptor antagonists decrease cardiac output, and this would be detrimental in heart 
failure, and this was the reason for not considering 1-adrenoceptor antagonists in heart 
failure.  However, we now know that 1-blockers have different effects in the failing than 
normal heart.  In heart failure, the number of 1-adrenoceptors is altered, and 1-adrenoceptor 
antagonists have been shown to increase cardiac output.  The 1-adrenoceptors, such as 
metoprolol, have been shown to decrease mortality and morbidity in subjects with heart 
failure.  1-adrenoceptor antagonists are now very commonly used in the treatment of heart 
failure. 
 
12.3.6 Digoxin 
Digoxin is derived from a plant source (the foxglove) and has been in medical use for dropsy 
(heart failure) since medieval times.  It is much more recently that it was discovered that the 
mechanism of action of digoxin is inhibition of the Na
+
K
+
ATP-ase that drives sodium and 
potassium exchange across membranes.  This leads to an increased force of myocardial 
contraction.  In heart failure, increase the force of the heart beat to increase cardiac output, 
which helps reverse the decreased cardiac output in heart failure.  However, “Digoxin has a 
very low therapeutic index, and at least 60% of the toxic dose is required to produce a 
therapeutic effect.  Because of this narrow safety margin, it has been argued, that if digoxin 
were to be introduced as a new drug today, it would be regarded as too dangerous for clinical 
use”.  But we still use digoxin! 
 
As the Na
+
K
+
ATP-ase is present on all cells, it is not surprising that digoxin has widespread 
effects, some of which are toxic.  On the cardiovascular system, digoxin is pro-arrhythmic 
i.e. it can cause cardiac arrhythmias.  Some of the toxic effects of digoxin help to identify it 
as the culprit.  For instance, digoxin causes visual disturbances such as disturbed colour 
vision, and halos around objects.  Digoxin also causes psychiatric problems such as delirium, 
fatigue, malaise, confusion, and abnormal dreams.  Digoxin can also cause gastro-intestinal 
toxicity such as anorexia, nausea, vomiting, and abdominal pain.  In life threatening digoxin 
toxicity, anti-digoxin immunotherapy is used intravenously. 
 
